FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914323946> ?p ?o ?g. }

• W2914323946 endingPage "1871" @default.
• W2914323946 startingPage "1871" @default.
• W2914323946 abstract "Abstract Background: Bruton tyrosine kinase (BTK) is a validated target for B-cell malignancies. The BTK inhibitor ibrutinib was approved in chronic lymphocytic leukemia, mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia. Acalabrutinib is a potent, highly selective, covalent BTK inhibitor with minimal off-target activity; it received accelerated FDA approval in October 2017 for the treatment of patients with MCL having ≥1 prior therapy. In addition to the approved covalent BTK inhibitors ibrutinib and acalabrutinib, clinical data in B-cell malignancies are available for spebrutinib (CC-292), tirabrutinib (ONO/GS-4059) and zanubrutinib (BGB-3111). We performed biochemical and cellular profiling of these 5 BTK inhibitors, investigating potency and selectivity. Methods: Two biochemical kinase assays assessed BTK inhibitor potency, with IC50 determination at a fixed time point (IMAP; Molecular Devices) or over time (LanthaScreen; Invitrogen); the latter was used to calculate binding kinetics. Kinome profiling was performed at a single dose (1 µM) using KINOMEscan (Eurofins DiscoverX). IC50 determinations were made using kinases with a Cys in the same position as the Cys481 residue in BTK, using assays developed in house (using IMAP and LanthaScreen) or at Thermo Fisher Scientific (Z'-LYTE) with IC50 determination at a fixed time point. On-target inhibition of BTK in cellular assays was evaluated using B-cell receptor-mediated activation of CD69 expression on peripheral B cells using human peripheral blood mononuclear cells (hPBMCs) or human whole blood (hWB). Off-target inhibition of epidermal growth factor receptor (EGFR) was evaluated in a cellular assay examining the effect of EGF-induced EGFR phosphorylation in A431 cells. Off-target inhibition of ITK and/or TXK was evaluated using T-cell receptor (TCR)-mediated activation of interleukin-2 expression in Jurkat T cells and CD25 cell surface expression using primary human peripheral T cells. Results: Based on biochemical binding kinetics, ibrutinib and zanubrutinib were the most potent BTK inhibitors (Table 1), followed by spebrutinib; acalabrutinib and tirabrutinib had comparable potency. Differences in potency were largely driven by differences in inactivation rates. However, differences in biochemical potency were lost (in part) in cellular assays using hPBMCs or hWB. EC50 values in hWB were <10 nM for ibrutinib, acalabrutinib and zanubrutinib. Spebrutinib had an EC50 of 140 nM in hWB, showing the greatest loss of potency versus biochemical assays and hPBMCs, going to the physiologically most relevant cellular experimental conditions (Table 2). Differences in overall kinase selectivity were observed among the BTK inhibitors (Figure 1; KINOMEscan). Acalabrutinib had the lowest hit rate; 1.5% of human wild-type kinases were inhibited >65% at 1 µM (excluding BTK). Kinase hit rate was also low for tirabrutinb (2.3%), whereas ibrutinib (9.4%), zanubrutinib (4.3%), and spebrutinib (8.3%) had higher hit rates. Acalabrutinib had a high selectivity for BTK over kinases with a Cys in the same position as the Cys481 residue in BTK (Table 2). Similar results were observed for tirabrutinib, whereas ibrutinib, spebrutinib and zanubrutinib were less selective in this panel of kinases with potential for off-target covalent binding by BTK inhibitors (Table 2). Acalabrutinib also had a higher selectivity for BTK over Src-family kinases than the other BTK inhibitors tested. Acalabrutinib and tirabrutinib had EC50 values >10 µM in the cellular assay of off-target inhibition of EGFR; ibrutinib, zanubrutinib, and spebrutinib had EC50 values of 0.07, 0.39, and 4.7 µM, respectively. No off-target inhibition was observed for acalabrutinib or tirabrutinib on TCR-mediated activation of T cells up to 10 µM. Ibrutinib, zanubrutinib, and spebrutinib had EC50 values <1 µM in Jurkat T cells. Similar results were observed in primary human peripheral T cells. Conclusion: BTK inhibitors in clinical development for B-cell malignancies had differing potency in biochemical assays, but these differences were lost (in part) in cellular assays, particularly in hWB. Among the BTK inhibitors tested, the greatest differentiation was observed in kinase selectivity profiles; acalabrutinib and tirabrutinib had the highest kinase selectivity. Disclosures Kaptein: Covaluation Pharma BV: Employment, Equity Ownership; Acerta Pharma BV: Consultancy, Equity Ownership; Apo-T BV: Consultancy. de Bruin:Acerta Pharma: Employment. Emmelot-van Hoek:Acerta Pharma: Employment. van de Kar:Acerta Pharma: Employment. de Jong:Acerta Pharma: Employment. Gulrajani:Acerta Pharma: Employment, Equity Ownership. Demont:Acerta Pharma: Employment. Covey:AstraZeneca: Equity Ownership; Acerta Pharma: Employment. Mittag:Acerta Pharma: Employment, Equity Ownership. Barf:Covaluation Holding BV: Employment, Equity Ownership; Acerta Pharma BV: Consultancy, Equity Ownership, Membership on an entity's Board of Directors or advisory committees." @default.
• W2914323946 created "2019-02-21" @default.
• W2914323946 creator A5003061294 @default.
• W2914323946 creator A5006877542 @default.
• W2914323946 creator A5014245796 @default.
• W2914323946 creator A5014658242 @default.
• W2914323946 creator A5036202180 @default.
• W2914323946 creator A5051654875 @default.
• W2914323946 creator A5061538635 @default.
• W2914323946 creator A5069649257 @default.
• W2914323946 creator A5078835680 @default.
• W2914323946 creator A5087432759 @default.
• W2914323946 date "2018-11-29" @default.
• W2914323946 modified "2023-10-14" @default.
• W2914323946 title "Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies" @default.
• W2914323946 doi "https://doi.org/10.1182/blood-2018-99-109973" @default.
• W2914323946 hasPublicationYear "2018" @default.
• W2914323946 type Work @default.
• W2914323946 sameAs 2914323946 @default.
• W2914323946 citedByCount "48" @default.
• W2914323946 countsByYear W29143239462019 @default.
• W2914323946 countsByYear W29143239462020 @default.
• W2914323946 countsByYear W29143239462021 @default.
• W2914323946 countsByYear W29143239462022 @default.
• W2914323946 countsByYear W29143239462023 @default.
• W2914323946 crossrefType "journal-article" @default.
• W2914323946 hasAuthorship W2914323946A5003061294 @default.
• W2914323946 hasAuthorship W2914323946A5006877542 @default.
• W2914323946 hasAuthorship W2914323946A5014245796 @default.
• W2914323946 hasAuthorship W2914323946A5014658242 @default.
• W2914323946 hasAuthorship W2914323946A5036202180 @default.
• W2914323946 hasAuthorship W2914323946A5051654875 @default.
• W2914323946 hasAuthorship W2914323946A5061538635 @default.
• W2914323946 hasAuthorship W2914323946A5069649257 @default.
• W2914323946 hasAuthorship W2914323946A5078835680 @default.
• W2914323946 hasAuthorship W2914323946A5087432759 @default.
• W2914323946 hasBestOaLocation W29143239461 @default.
• W2914323946 hasConcept C137061746 @default.
• W2914323946 hasConcept C170493617 @default.
• W2914323946 hasConcept C184235292 @default.
• W2914323946 hasConcept C185592680 @default.
• W2914323946 hasConcept C202751555 @default.
• W2914323946 hasConcept C203014093 @default.
• W2914323946 hasConcept C2777938653 @default.
• W2914323946 hasConcept C2778461978 @default.
• W2914323946 hasConcept C2779878957 @default.
• W2914323946 hasConcept C42362537 @default.
• W2914323946 hasConcept C502942594 @default.
• W2914323946 hasConcept C54174078 @default.
• W2914323946 hasConcept C55493867 @default.
• W2914323946 hasConcept C57992300 @default.
• W2914323946 hasConcept C71924100 @default.
• W2914323946 hasConcept C90059517 @default.
• W2914323946 hasConcept C98274493 @default.
• W2914323946 hasConceptScore W2914323946C137061746 @default.
• W2914323946 hasConceptScore W2914323946C170493617 @default.
• W2914323946 hasConceptScore W2914323946C184235292 @default.
• W2914323946 hasConceptScore W2914323946C185592680 @default.
• W2914323946 hasConceptScore W2914323946C202751555 @default.
• W2914323946 hasConceptScore W2914323946C203014093 @default.
• W2914323946 hasConceptScore W2914323946C2777938653 @default.
• W2914323946 hasConceptScore W2914323946C2778461978 @default.
• W2914323946 hasConceptScore W2914323946C2779878957 @default.
• W2914323946 hasConceptScore W2914323946C42362537 @default.
• W2914323946 hasConceptScore W2914323946C502942594 @default.
• W2914323946 hasConceptScore W2914323946C54174078 @default.
• W2914323946 hasConceptScore W2914323946C55493867 @default.
• W2914323946 hasConceptScore W2914323946C57992300 @default.
• W2914323946 hasConceptScore W2914323946C71924100 @default.
• W2914323946 hasConceptScore W2914323946C90059517 @default.
• W2914323946 hasConceptScore W2914323946C98274493 @default.
• W2914323946 hasIssue "Supplement 1" @default.
• W2914323946 hasLocation W29143239461 @default.
• W2914323946 hasOpenAccess W2914323946 @default.
• W2914323946 hasPrimaryLocation W29143239461 @default.
• W2914323946 hasRelatedWork W1830209188 @default.
• W2914323946 hasRelatedWork W2047415399 @default.
• W2914323946 hasRelatedWork W2168006562 @default.
• W2914323946 hasRelatedWork W2557815702 @default.
• W2914323946 hasRelatedWork W2614001962 @default.
• W2914323946 hasRelatedWork W2955099322 @default.
• W2914323946 hasRelatedWork W2981016883 @default.
• W2914323946 hasRelatedWork W2990290302 @default.
• W2914323946 hasRelatedWork W3217096222 @default.
• W2914323946 hasRelatedWork W4249624647 @default.
• W2914323946 hasVolume "132" @default.
• W2914323946 isParatext "false" @default.
• W2914323946 isRetracted "false" @default.
• W2914323946 magId "2914323946" @default.
• W2914323946 workType "article" @default.